SINCRO

  Cat. No.:  DC11072  
SINCRO
Chemical Structure
1494619-28-1
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes.
Cas No.: 1494619-28-1
Chemical Name: N-{3-[(1,4'-bipiperidin)-1'-yl]propyl}-6-[4-(4-methylpiperazin-1-yl)phenyl]picolinamide
Synonyms:
SMILES: C(C(NCCCN1CCC(N2CCCCC2)CC1)=O)1=NC(C2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1
Formula: C30H44N6O
M.Wt: 504.723
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes; SINCRO (STING-mediated interferon-inducing and cytotoxic reagent, original) shows a STING-independent cytotoxic activity against cancer cells, SINCRO does not evoke DNA double-strand break or caspase-3 cleavage, induces cell death in a manner different from conventional apoptosis-inducing pathways; significantly attenuates in vivo tumor growth by both type I IFN-dependent and independent mechanisms.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC11179 STING CDN agonist IFM Therapeutics STING CDN agonist IFM Therapeutics is a synthetic cyclic dinucleotide (CDN) agonist of STING, stimulates potent immunity against cancer..
DC11072 SINCRO SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes.